<DOC>
	<DOCNO>NCT00875433</DOCNO>
	<brief_summary>A phase II trial ass impact afatinib ( BIBW 2992 ) heart ( QTcF ) effectiveness afatinib ( BIBW 2992 ) treat certain cancer . Cancers study include glioblastoma cancer spread brain ( metastasis ) .</brief_summary>
	<brief_title>Afatinib ( BIBW 2992 ) QTcF Trial Patients With Relapsed Refractory Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Male female patient age least 18 year old . 2 . Histologically cytologically confirm diagnosis solid malignant tumour , know express EGFR/HER2 either refractory standard therapy , standard treatment available ( include patient brain metastasis ) . 3 . At least one tumor lesion accurately measure compute tomography ( CT ) magnetic resonance imaging ( MRI ) least one dimension long diameter record great equal 20 mm use conventional technique great equal 10 mm spiral CT scan . 4 . Life expectancy least 3 month . 5 . Written inform consent consistent ICHGCP guideline . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0,1 2 . 7 . Patients must recover previous surgery . 8 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) duration trial participation . Female patient reproductive potential must negative serum pregnancy test within 7 day trial enrolment . Breast feed mother exclude since agent may toxic infant . For patient Glioma brain metastasis follow additional inclusion criterion apply : 1 . Histologicallyconfirmed WHO Grade IV malignant glioma first episode recurrence prior combine chemoradiotherapy . Patients prior lowgrade glioma eligible histological assessment demonstrate transformation WHO Grade IV malignant glioma . 2 . Bidimensionally measurable disease minimum measurement 1 cm ( 10 mm ) one diameter Gd MRI perform within 14 day prior first treatment ( Day 1 ) . Exclusion criterion : Major exclusion criterion ; 9 . Radiotherapy within past 2 week prior treatment trial drug . 10 . Chemo , hormone ( megestrol acetate steroid require maintenance noncancer therapy ) immunotherapy within past 4 week first drug administration . 11 . Patients completely recover therapyrelated toxicity previous chemo , hormone , immuno , radiotherapy CTC &lt; Grade 1 . Prior chemotherapy allow complete least 4 week prior first trial treatment ( 6 week mitomycin C nitrosoureas ) patient recover acute toxicity therapy . 12 . Prior treatment EGFR target therapy treatment EGFR HER2 inhibit drug within past four week start therapy concomitantly trial . 15 . History clinically significant uncontrolled cardiac disease , include congestive heart failure , angina , myocardial infarction , arrhythmia , include New York Heart Association ( NYHA ) functional classification 3 . 16 . Cardiac leave ventricular function rest ejection fraction &lt; 50 % measure multigated blood pool image heart ( MUGA scan ) Echocardiogram . 17 . QTcF interval &gt; 470 m screening . 18 . PRinterval &gt; 230 m screening . 19 . QRSinterval &gt; 120 m screening . 20 . STsegment T/Uwave abnormality screen , assessed cardiology specialist central lab . 21 . Absolute neutrophil count ( ANC ) &lt; 1,500/mm3 . 22 . Platelet count &lt; 100,000 / mm3 . 23 . Bilirubin &gt; 1.5 mg / dl ( &gt; 26 micro mol / L , SI unit equivalent ) . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &gt; equal three time upper limit normal ( related liver metastasis &gt; five time upper limit normal ) . 24 . Serum creatinine &gt; 1.5 time upper normal limit calculated/measured creatinine clearance &gt; equal 45 ml / min . 25 . Patients know Interstitial Lung Disease ( ILD ) For Patients glioma brain metastasis additional exclusion criterion apply ; 1 . Patients untreated symptomatic brain metastasis . Patients treat , asymptomatic brain metastasis eligible change brain disease status least four ( 4 ) week , history cerebral oedema bleed past four ( 4 ) week . Steroids allow . Antiepileptic therapy allow change anticipate within initial 14 day treatment ( QTCevaluation ) . 2 . Less 4 week radiotherapy start study treatment , unless new enhance lesion outside radiation field radiologically progressive two consecutive MRI scan least four week apart biopsyproven recurrence . 3 . Less two week surgical resection ( one week prior stereotactic biopsy ) major surgical procedure . 4 . Less two week previous chemotherapy ( 6 week nitrosureas ) . 5 . Less four week prior treatment bevacizumab . 6 . Treatment investigational drug ; participation another clinical study within past 2 week start therapy concomitantly study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>